Преимущества применения деносумаба при остеопорозе (обзор данных литературы)
https://doi.org/10.21518/2079-701X-2013-2-2-72-77
Аннотация
На сегодняшний день в арсенале практического врача имеется достаточное количество эффективных лекарственных препаратов, используемых для патогенетической терапии остеопороза. Согласно последним рекомендациям Российской ассоциации по остеопорозу, к препаратам первого выбора для лечения остеопороза, наряду с азотсодержащими бисфосфонатами и стронция ранелатом, относится и деносумаб, клиническая эффективность которого в отношении снижения риска внепозвоночных и позвоночных переломов доказана в длительных многоцентровых клинических испытаниях.
Об авторах
О. Б. Ершова
Ярославская государственная медицинская академия
Россия
Россия
А. В. Назарова
ГУЗ ЯО КБ СМП им. Н.В. Соловьева
Россия
Россия
Список литературы
1. Клинические рекомендации по профилактике и ведению больных с остеопорозом. Под ред. Лесняк О.М. Ярославль 2012– 24с.
2. Aspenberg P., Schilcher J., Fahlgren A. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bonewith remodelling at the crack. Acta Orthop. 2010;81(4):460–462.
3. Rizzoli R., Akesson K., Bouxsein M. et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011;22:373–390.
4. Shane E., Burr D., Ebeling P.R. et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267–2294.
5. Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bispho sphonate. Acta Orthop 2009; 80 (4): 413–415.
6. Miller P.D. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskel Dis 2011; 3(6): 271–282.
7. Boyle, W.J., Simonet, W.S. and Lacey, D.L. Osteoclast differentiation and activation. Nature 2003; 423: 337–342.
8. Miller, P.D., Bolognese, M.A., Lewiecki, E.M. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43(2): 222–229.
9. Muschitz C., Fahrleitner-Pammer A., Huber J. et al. Update on denosumab in postmenopausal osteoporosis--recent clinical data. Wien Med Wochenschr. 2012;162(17-18): 374–379.
10. Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med Wkly 2012;142: w13624.
11. Sutton E.E., Riche D.M. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother. 2012; 46(7-8):1000–1009.
12. Lin T., Wang C., Cai X.Z. et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women withosteoporosis: a meta-analysis. Int J Clin Pract. 2012; 66(4):399–408.
13. Suda, T., Takahashi, N., Udagawa, N. У. et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20: 345–357.
14. Klawansky S., Komaroff E., Cavanaugh P.F.J. et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14:570–576.
15. Jamal S.A., Ljunggren O., Stehman-Breen C. et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26(8):1829–1835.
16. Block G.A., Bone H.G., Fang L., Lee E., Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471–1479.
17. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72-81.
18. C. Roux, A. Fahrleitner-Pammer et al. A Randomized Study to Evaluate the Safety and Efficacy of Denosumab and rezidronate in Postmenopausal Women ASBMR; Minneapolis, MN; October 12—15, 2012.
19. Recknor et al. A Randomized Open-label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Suboptimally Treated With Daily or Weekly Bishosphonates (TTI study) ASBMR; Minneapolis, MN; October 12—15, 2012.
20. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
21. Boonen S, Adachi JD, Man Z et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrin Metab. 2011;96:1727-1736.
Рецензия
Для цитирования:
Ершова О.Б., Назарова А.В. Преимущества применения деносумаба при остеопорозе (обзор данных литературы). Медицинский Совет. 2013;(2-2):72-77. https://doi.org/10.21518/2079-701X-2013-2-2-72-77
For citation:
Ershova O.B., Nazarova A.V. Advantages of using denosumab for osteoporosis. Meditsinskiy sovet = Medical Council. 2013;(2-2):72-77. (In Russ.) https://doi.org/10.21518/2079-701X-2013-2-2-72-77
Просмотров: 227
Послать статью по эл. почте 